Solomon Moshkevich - 01 Jul 2025 Form 4 Insider Report for Natera, Inc. (NTRA)

Role
PRESIDENT, CLINICALDIAGNOSTICS
Signature
/s/ Vincent Fontanilla, Attorney-in-Fact
Issuer symbol
NTRA
Transactions as of
01 Jul 2025
Net transactions value
-$500,305
Form type
4
Filing time
03 Jul 2025, 21:05:06 UTC
Previous filing
04 Jun 2025
Next filing
30 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN /s/ Vincent Fontanilla, Attorney-in-Fact 03 Jul 2025 0002010019

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTRA Common Stock Sale $65,551 -400 -0.3% $163.88 132,805 01 Jul 2025 Direct F1, F2
transaction NTRA Common Stock Sale $33,197 -200 -0.15% $165.98 132,605 01 Jul 2025 Direct F1, F3
transaction NTRA Common Stock Sale $352,730 -2,109 -1.6% $167.25 130,496 01 Jul 2025 Direct F1, F4
transaction NTRA Common Stock Sale $48,827 -291 -0.22% $167.79 130,205 01 Jul 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.55 to $164.08 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.62 to $166.35 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.64 to $167.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.